← Search & browse all drugs
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › PROTEIN KINASE INHIBITORS › Other protein kinase inhibitors
sorafenib
L01EX02
Forms & Strengths
- Tablets: 200mg
- Oral dosage form
Adult Dosing
- 400mg twice daily for renal cell carcinoma and HCC
- Initiate with 400mg daily for flakes of child-Pugh class B and C in primary HCC
Pediatric Dosing
- Not established for patients under 18 years old
- Avoid use due to potential for growth effects
Indications
- Renal cell carcinoma (RCC)
- Hepatocellular carcinoma (HCC)
- Thyroid cancer
Mechanism of Action
- Multikinase inhibitor of Raf-1, B-Raf, c-Kit, FLT-3, RET, and VEGFR-2,3
- Inhibits tumor growth and angiogenesis
Contraindications
- Hypersensitivity to sorafenib
- Pregnancy
Adverse Reactions
- Fatigue
- Anorexia
- Weight loss
- Diarrhea
- Hypertension
- Hand-foot skin reaction
Drug Interactions
- Warfarin: Avoid concomitant use
- CYP3A4 inhibitors or inducers: use with caution and close monitoring
- P-glycoprotein substrates: avoid use if possible
Curated Content: Needs Vetting Before Put to Clinical Use